Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527325) titled 'Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of California, Irvine
Condition:
Melanoma (Skin)
Intervention:
Drug: Fianlimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 30, 2026
Target Sample Size: 35
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07527325
Published by HT Digital Content Services with p...